Introduction
The c-Src proto-oncogene has been strongly implicated in the development, growth, progression, and metastasis of a number of human cancers including those of the colon, breast, pancreas, and brain. Our working hypothesis is that Src may play a central role in these processes aecting cancer outcome. The evidence underlying this hypothesis is largely based on the observation that both Src protein levels and, to a greater degree, Src protein kinase activity, are frequently elevated in human neoplastic tissues when compared to adjacent normal tissues. Moreover, these levels appear to increase with the stage of disease. Similarly, increased Src protein kinase activity has been observed in numerous human cancer cell lines derived from these tumors.
Although the precise mechanism for the high levels of Src activation in human cancer has not been clearly elucidated, several mechanisms have been proposed, suggesting that the process is multifactorial (Bolen et al., 1987b; Ottenho-Kal et al., 1992; Mao et al., 1997) . The speci®c activity of Src protein kinase may be increased by direct or indirect interaction with receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) (Tice et al., 1999; Luttrell et al., 1994; Mao et al., 1997) platelet derived growth factor receptor (PDGFR) (Courtneidge et al., 1993) ®broblast growth factor receptor (FGFR) (LaVallee et al., 1998) , colony simulating factor-1 receptor (CSF-1R) (Courtneidge et al., 1993; Levitzki, 1996) , HER2/neu (Luttrell et al., 1994) , and hepatocyte growth factor receptor (c-Met) (Rahimi et al., 1998) . For example, it has been demonstrated that the combination of EGFR and Src expression in ®broblasts leads to synergistic levels of tumorigenicity when compared with expression of EGFR or Src alone (Maa et al., 1995; Mao et al., 1997) . Observations such as these provide strong evidence that Src does not act alone but may require partnerships for full expression of activity. Another potential mechanism for Src activation may relate to reductions in the levels or activity of Csk, the enzyme known to phosphorylate the negative regulatory tyrosine residue of c-Src (Tyr 530) (Masaki et al., 1999) . Similarly, enhanced activity of phosphatases known to dephosphorylate the regulatory Tyr 530 may cause Src activation (Bjorge et al., 1996; Egan et al., 1999; Peng and Cartwright, 1995) . Recently, a mutational basis for Src activation was identi®ed in a small subset of advanced human colon cancers, suggesting a potential genetic link between Src activation and cancer development, progression, and metastasis .
The eect of Src over-expression and activation appears to be pleiotropic. Numerous Src substrates are phosphorylated in tumor cells harboring activated forms of Src, and, many of these Src substrates have been linked to processes inducing tumorigenicity and metastasis (Brown and Cooper, 1996) . Furthermore, these dramatic alterations in signal transduction likely in¯uence multiple downstream transcriptional events. These events include alterations in homotypic adhesion, angiogenesis, tumor cell invasivity, tumor growth, and apoptosis, all of which play a signi®cant role in the development of the metastatic phenotype. The extensive presence of activated Src in human cancers and its potential role in their development and progression, makes Src an appealing target for drug discovery eorts.
Activated Src is common in human tumors
The eects of elevated Src kinase activity have been extensively studied both in vitro using a variety of human neoplastic cell lines (Budde et al., 1994; Rosen et al., 1986; Biscardi et al., 1998; Bjorge et al., 1996; Bolen et al. 1987a; Cartwright et al., 1989; Weber et al., 1992; Lutz et al., 1998) and in vivo with murine models (Biscardi et al., 1998; Irby et al., 1999; Staley et al., 1997; Wiener et al., 1999) . Using these systems, investigators have studied modes of Src activation, eects of Src on tumor initiation and progression, and eects of tyrosine kinase and antisense inhibitors on cell behavior. These studies illustrate the complex network of Src interacting proteins that impact on numerous signal transduction pathways.
Since the early 1980s, increased Src kinase activity has been reported in various, apparently unrelated human cancers. Elevated Src protein levels have been Oncogene (2000) 19, 5636 ± 5642 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: TJ Yeatman found in many cancers, although the protein level may not accurately re¯ect the speci®c protein kinase activity. For this reason, reliable kinase assays using exogenous substrates were developed to determine the speci®c activity of the protein. Results from numerous studies re¯ect the increase of Src speci®c activity in human tumors and in cell lines derived from those tumors (Cartwright et al., 1989 (Cartwright et al., , 1990 Budde et al., 1994; Jacobs and Rubsamen, 1983; Mao et al., 1997; Masaki et al., 1998 Masaki et al., , 2000 Rosen et al., 1986; Verbeek et al., 1996) .
Breast cancer
Src kinase activity, from 4 ± 20-fold higher than normal tissues, has been found in human mammary carcinomas (Egan et al., 1999; Jacobs and Rubsamen, 1983; Ottenho-Kal et al., 1992; Rosen et al., 1986; Verbeek et al., 1996) . Similarly, cell lines derived from these tumors display up to a 30-fold elevation in Src activity. Recent data has suggested some of this activity may be attributable to the action of phosphatases resulting in dephosphorylation of Tyr 530 (Egan et al., 1999) . Rosen et al. (1986) reported an elevated Src kinase activity in breast tumors with relatively normal Src protein levels compared to normal tissue. On the other hand, Verbeek et al. (1996) presented immunohistochemical evidence that a 4 ± 30-fold increase in Src activity was accompanied by an increase in Src protein levels. Ottenho-Kal et al. (1992) found that 72/72 breast cancers showed an increase in tyrosine kinase activity, 70% of which was attributed to c-Src or Src like kinases.
Activated Src in mammary tumors has been well studied in transgenic mice. Mice expressing viral polyoma middle T antigen under the control of the MMTV promoter produce highly metastatic mammary tumors with elevated c-Src kinase activity (Guy et al., 1994) . found that mice overexpressing the neu oncogene also develop mammary tumors with 6 ± 8-fold higher c-Src kinase activity than adjacent normal tissue. These are two examples of activated Src, one an example of a viral protein binding and activating Src, causing tumors, and the other an example of a receptor tyrosine kinase causing Src activation and subsequent mammary tumors. Nude mouse experiments (Biscardi et al., 1998) with breast cancer cell lines over-expressing both c-Src and HER1 (MDA-MB-468 and MDA-MB-231) compared to cell lines over-expressing only c-Src (MCF7 and ZR-75-1) revealed increased tumorigenicity in mice injected with the MDA lines. This supports the hypothesis that Src activation can be mediated through HER1 interactions.
Colon cancer
The c-src proto-oncogene has frequently been implicated in the initiation and progression of human colon cancer, and in resultant metastases (Bolen et al., 1987a; Cartwright et al., 1989 Cartwright et al., , 1990 Cartwright et al., , 1994 Talamonti et al., 1991; Termuhlen et al., 1993; Weber et al., 1992) . Src activity is increased 5 ± 8-fold in the majority of colon tumors. This elevation of Src activity, and of the related Yes activity, is an early event, occurring even in premalignant tissues (Cartwright et al., 1994) and adenomatous polyps (Cartwright et al., 1990; Pena et al., 1995) . Activity is apparently high in malignant polyps and in benign polyps that contain villous change or severe dysplasia, which are at greatest risk for developing cancer. Src activity was also found to be elevated in mildly dysplastic epithelia (6 ± 10-fold) when compared directly with adjacent non-dysplastic epithelia in ulcerative colitis, increasing further in severely dysplastic tissue which is at greatest risk of developing cancer (Cartwright et al., 1994) .
A role for Src in tumor progression is poignantly illustrated by observations that Src activity increases with the progression of colon tumors, being higher in primary tumors than in polyps and higher yet in metastatic liver lesions (Talamonti et al., 1991) . The trend is re¯ected in six paired samples of synchronous primary and metastatic lesions from the same patient. While Src protein levels vary widely between patients, the activity level increases in liver metastases over that of synchronous primary tumors ± several fold greater than the increases in Src protein levels. Further dierences exist in the levels of activated Src seen in colorectal metastases to extrahepatic sites (Termuhlen et al., 1993) . In addition, colorectal metastases to abdomen, pelvis, and thorax showed a signi®cant increase in activity over hepatic metastases. These data raise the question as to whether the site of metastasis in¯uences the speci®c activity of Src or whether the speci®c activity of Src in¯uences the site of the metastatic lesion.
The in¯uence of Src in colon cancer has also been explored by examination of Src levels in colon tumors of various dierentiation states. The reported results are interesting but not always intuitive. Weber et al. (1992) reported that the highest levels of Src activity in human colon tumors occurred in moderately to well dierentiated tumors, and the levels appear fairly normal in poorly dierentiated colon tumors, a ®nding supported by various tumor cell lines. Park et al. (1993) and Park and Cartwright (1995) reported an increase in Src as well as the Src family kinase, Yes, in both colonic cell lines and in primary colon cancers, but these studies showed a downregulation of Src kinases in fully dierentiated cells. These results, on the surface, are dicult to interpret knowing that poorly dierentiated tumors are biologically more aggressive than well-dierentiated tumors. The majority of colorectal liver metastases, however, are in fact well-tomoderately dierentiated and this prevalence may explain the observed results.
The role of Src in colon cancer has been recently examined using the nude mouse model injected with various colon cancer cell lines . Staley et al. (1997) transfected the colon cancer cell line HT 29 with an antisense vector designed to reduce c-Src expression but not c-Yes expression. When injected into nude mice, these cells formed slowly growing tumors with a proliferation rate retarded further than the reduced proliferation rate of parental cells grown in culture. In contrast, cells stably transfected with a sense vector showed no dierence in proliferation in culture nor in nude mice from wild-type HT 29 cells. In a second study attempting to determine the phenotypic eects of wild-type c-Src over-expression on human colon cancer cells, c-Src-transfected KM12C colon cancer cells expressing up to 10-fold more c-Src than wild-type cells were injected subcutaneously and intrasplenically into nude mice ). Cells with a higher level of c-Src expression formed more rapidly growing tumors than did wild-type cells, but did not form liver metastases. Interestingly, transfected and wild-type cells grown in vitro showed similar proliferation rates. These two studies indicate that, ®rst, the level of Src and its activity alters the rate of tumor growth proportionally in vivo, and, second, growth rates in vitro do not necessarily re¯ect the growth rates of cells in vivo. This suggests that tumor cell growth is greatly in¯uenced by the microenvironment, and perhaps indicates the potential for Src activity in the tumor cell to aect the expression of tumor promoting proteins by the host. These studies also demonstrate that overexpression of wild-type c-Src alone, while clearly aecting tumor growth in vivo, may be insucient to induce the metastatic phenotype.
Pancreatic cancer
Src activity has recently been studied in pancreatic cancer. Lutz et al. (1998) examined pancreatic ductal carcinomas as well as pancreatic cell lines for elevated Src protein levels and kinase activity. Src protein levels were elevated in 13/13 pancreatic cancers and in 14/17 pancreatic cell lines. Kinase activity was only detectable in cancer cells and this activity did not correlate with either the c-Src or Csk protein levels. Further studies using the tyrosine kinase inhibitor, herbimycin A, indicated that the Src activity was instrumental in promoting the growth of pancreatic tumor cells. One method by which Src increases pancreatic tumor growth was suggested by Flossmann-Kast et al. (1998) . This group found that Src causes an increase in the number of insulin-like growth factor receptor (IGF-R) molecules per cell, thus enhancing IGF-dependent growth. In a another study based on a rat model of pancreatic carcinogenesis (Visser et al., 1996) , an increase in Src kinase activity correlated positively with the number of lesions present in the pancreas. This increase in activity was accompanied by a relocalization of c-Src protein to the nucleus, suggesting a role for Src in gene regulation.
Miscellaneous cancers
Elevated Src protein levels and/or kinase activity has been reported in lung (50 ± 80%) (Mazurenko et al., 1992) , neural (23/27 neuroblastomas, 3/3 retinoblastomas) (Bjelfman et al., 1990; Bolen et al., 1985) , ovarian (Budde et al., 1994; Wiener et al., 1999) , esophageal (3 ± 4-fold increases in activity in Barrett's esophagus and sixfold elevations in adenocarcinomas) (Kumble et al., 1997) and gastric cancers (Takeshima et al., 1991) , as well as melanoma (Bjorge et al., 1996) and Kaposi's sarcoma (Munshi et al., 2000) . Src family kinases Lck, Lyn, and Fgr have similarly been shown to be activated during leukemic cell growth (Abts et al., 1991) (Dai et al., 1998; Danhauser-Riedl et al., 1996; Roginskaya et al., 1999) .
Src as a potential oncogene
The majority of the data supporting a role for Src as a potential oncogene in human cancer is derived from experiments utilizing v-Src protein or other activated forms of Src to induce cellular transformation, tumorigenicity, tumor progression, and metastasis. The v-src gene, encoded by Rous sarcoma virus, was the ®rst transmissible gene found to induce tumors. It was originally discovered by Peyton Rous in 1911 (Rous, 1911) as a transmissible agent that would produce tumors in chickens. The protein product of this gene, v-Src, is a tyrosine kinase with a cellular homolog, c-Src, which is found in normal cells and presumed to be a protooncogene (Czernilofsky et al., 1980) (Stehelin et al., 1976) . The structure of the two proteins is similar, but the regulatory carboxyl terminus of v-Src is truncated (resulting in activation) and numerous dierences in amino acid sequence throughout the protein exist (enhancing the activation) (Jove and Hanafusa, 1987) . While the two proteins perform the same function, the kinase activity of v-Src and its capacity to transform are much higher than c-Src. Moreover, cellular transformation by v-Src has been reported to produce a 10-fold elevation in protein phosphotyrosine over that produced by c-Src. Despite relatively modest protein expression levels in cells, v-Src invariably results in high levels of cellular transformation as distinguished by altered cellular morphology, cytoskeletal reorganization, proliferation under low serum conditions, and anchorage independent growth. The end result of these changes in vitro is the enhanced tumorigenicity in vivo. The phosphorylation of numerous cellular substrates on tyrosine residues by v-Src is likely responsible for the eects on cellular transformation. These phosphorylation events are presumed to aect proteins which regulate cell growth and dierentiation and include, among others, transcription factors, members of signal transduction cascades, and growth factor receptors (Brown and Cooper, 1996; Thomas and Brugge, 1997) .
Because oncogenes may, in some cases, represent fetal genes inappropriately expressed in adult tissues, further evidence for Src's role as an oncogene is derived from observations suggesting that it is involved in dierentiation of fetal tissues. This is especially true in neural tissues (Bjelfman et al., 1990) , where dierentiating vertebrate neurons express high levels of c-Src with elevated kinase activity. Similar events occur in tumors of neuronal origin (Bjelfman et al., 1990 ). An overproduction of c-Src by itself, however, is, at best, minimally transforming, suggesting that increased Src activity may play more of a role in tumor progression than in tumorigenesis (Biscardi et al., 1999a) .
Until recently, the genetic evidence for Src as a human oncogene has been lacking. While numerous mutant forms of avian v-Src have been identi®ed and multiple chicken c-Src mutants have been constructed, none have been previously observed in humans. The recent observation that an activating mutation (Src 531) exists in a small subset of advanced human colon cancers with high Src activity lends credence to the hypothesis that Src may have oncogeneic potential (Irby et al., 1999) . Src 531 was shown to induce cellular transformation, and augment tumor growth and metastatic potential in ®broblasts.
Mode of Src activation
While elevation of Src protein levels is apparently common to a large number of cancers, this elevation is often modest when compared to the fold-increases of Src kinase activity that have been observed. These data suggest the relative importance of Src activation in human tumor development and progression. Several possible explanations exist for the activation of Src kinase in cancer. First, Src can be activated by receptor tyrosine kinases such as EGFR and HGF receptor (Maa et al., 1995; Mao et al., 1997) . These receptors have been known to be active in the progression of cancer, and, in turn, may activate Src. It has been suggested that the association between c-Src and these receptor tyrosine kinases is instrumental in malignant transformation (Luttrell et al., 1994) .
A second possibility is that Src is activated posttranslationally. Several modes of post-translational activation exist: insucient Csk activity, increased activity of Src phosphatases, or interaction with viral or cellular proteins. Csk activity inactivates the human Src protein by phosphorylation of the negative regulatory tyrosine 530 (avian Tyr 527). A decrease in the level of Csk protein or production of a defective Csk would permit a more active form of Src. While studies of pancreatic carcinomas show no correlation between Src activity levels and Csk levels , in hepatocarcinomas, activated Src has been shown to be correlated with decreased Csk levels (Masaki et al., 1999) . Although this mode of activation is anticipated, it does not account for all of the activated Src kinase in human tumors. Studies of human breast cancer cell lines demonstrated cells with elevated Src kinase activity, with or without increased Src protein levels. A set of these breast cancer cells displayed active phosphatases that are believed to activate the Src by dephosphorylating the regulatory Tyr 530 (Egan et al., 1999) . The mouse models of mammary carcinoma indicated above are examples of post-translational modi®cation by cellular or viral proteins. In the event of post-translational modi®ca-tion, the eects to the cell will be more limited to Srcspeci®c eects, not aecting parallel pathways.
Thirdly, there exists the possibility of activating mutations in the SRC gene. While a number of induced mutations in Src have been studied and found to be transforming, only one naturally occurring human mutation has been reported (Irby et al., 1999) . Using a very sensitive, mutant allele-speci®c assay, a single base pair C-T transition was found in a subset of colon cancer liver metastases and advanced colon cancer primary lesions (Irby et al., 1999) . This mutation was identi®ed in codon 531 and resulted in truncation of the Src protein leading to Src activation. Src 531 was shown to be modestly transforming in focus formation assays and led to increased levels of metastatic lung colonization. Recent attempts at replicating this work were not successful possibly because either insensitive RFLP assays were utilized as the sole screening assay, or a preponderance of advanced lesions were excluded from study, without the bene®t of microdissection to eliminate the presence of normal contaminating tissues or cellular in®ltrates. (Daigo et al., 1999; Wang et al., 2000) . Detection of uncommon heterozygous mutations likely requires a more sensitive mutant allele speci®c PCR based assay where the mutant allele is the target of ampli®cation. Because colon tumors tend to have large amounts of normal in®ltrating cells such as lymphocytes and monocytes, it is also critical that tumor specimens be carefully microdissected prior to analysis.
Another apparently unique mode of activation was found in neruroblastoma cells, which display a 20 ± 40-fold increase in Src kinase activity. The cells with activated Src harbored a Src protein containing an additional tyrosine in the amino-terminal portion. Phosphorylation of this tyrosine increased the activity of c-Src in these cell lines (Bolen et al., 1985) . A neuronal form of Src has been subsequently identi®ed in developing neuroblasts and neurons. This neuronal Src, pp60c-srcN, was also found in neuroblastomas (9 of 12) and retinoblastomas, but not in other childhood tumors (Bjelfman et al., 1990) . These data suggest that perhaps other forms of Src are present, but as yet undetected or indistinguishable from the known Src family kinases by current detection methods.
A ®nal vehicle for Src activation may relate to the absence of regulatory proteins. The recently identi®ed drs gene is capable of suppressing v-Src transformation of cells (Shimakage et al., 2000) . This protein is reduced in a variety of human cancer cell lines, including colon, bladder, and ovary. While most normal tissues were found to express the drs gene, drs mRNA was minimally detected in all human colon adenocarcinoma cells tested. In another study, Brummer et al. (1995) found an association between Src and the biliary glycoprotein CD66. CD66 is downregulated in many colon cancers, perhaps resulting in the disregulation of c-Src. In some cases, Src apparently causes the destruction of an anti-tumorigenic protein.
Abi is a protein that interacts with Abl, inhibiting the oncogenic activity of Abl. Src triggers the destruction of Abi through the ubiquitin-proteosome pathway, thus allowing Abl to exert its oncogenic potential (Dai et al., 1998) . Bcr-Abl positive leukemias are de®cient in Abi protein, and suggests a mechanism by which activated Src can in¯uence oncogenesis.
Rami®cations of Src activation
Src has been implicated in the progression and metastasis of many human cancers. Increased Src activity has been shown to increase the growth rate of cells , reduce adhesion between cells (Hamaguchi et al., 1993) , and increase metastatic potential of cells (Irby et al., 1999) . While the the downstream targets of c-Src are still being de®ned, Src has been shown to interact with regulatory pathways in the cell cycle and signal transduction cascades involved with proliferation. For example, Src interacts with Ras signaling pathways (Haas et al., 2000; Machida et al., 2000; Odajima et al., 2000; Tokumitsu et al., 2000) and Ras function has been shown to be necessary for v-Src transformation of human epithelial cells (Tokumitsu et al., 2000) . Src activation provides a link to the Ras/MAPK cascade (Haas et al., 2000) . Activated Src, either mutant Src 531 or v-Src, has been shown to activate the transcription factor Stat3 (Yu et al., 1995) . Moreover, blocking Stat3 signaling has been shown to suppress Src transformation (Bromberg et al., 1998; Turkson et al., 1998; Wen et al., 1999) . Each of these events alone may be capable of enhancing tumor growth (Bowman et al., 2000) . A summary of these concepts linking Src activation to the development of the metastatic phenotype is presented in Figure 1 .
Activated Src also associates with the adhesion proteins, catenins and cadherins (Hamaguchi et al., 1993) . Furthermore, Src appears to be activated by integrin-mediated substrate adhesion, which in turn, causes inactivation and disruption of the cadherin/ catenin complex, and induces a metastatic phenotype (Genda et al., 2000; Hamaguchi et al., 1993) .
Src associates with EGFR, and is both activated by and activates the receptor in a synergistic fashion (Biscardi et al., 1999b; Tice et al., 1999) . As many human cancers are known to over-express both EGFR and c-Src, it is reasonable that they have coordinated functions. EGFR has been shown to activate c-Src kinase, and inhibition of EGFR reduces Src activity to basal levels in colon cancer cell lines . Furthermore, association of c-Src with EGFR results in phosphorylation of EGFR Tyr 845 and subsequent activation of the receptor (Biscardi et al., 1999b) . This results in a synergistic increase in EGF mediated DNA synthesis, growth in soft agar, and tumorigenesis over cells over-expressing either protein alone (Maa et al., 1995) .
Src induces vascular epithelial growth factor (VEGF), enhancing angiogenesis (Fleming et al., 1997; Munshi et al., 2000) . The relationship between Src and VEGF appears to be somewhat reciprocal. VEGF induced activity is negated with the inhibition of Src activity. Src also appears to provide a link in VEGF signaling of MAPK pathways that contributes to tumor proliferation and motility (Munshi et al., 2000) .
Src is capable of enhancing tumor growth through the induction of Bcl-x L expression (Karni et al., 1999) . Bcl-x L is an anti-apoptotic protein that is transcriptionally regulated by Stat3 (Bromberg et al., 1999; Catlett-Falcone et al., 1999) . Other Stat3-regulated genes implicated in cell cycle control and oncogenesis are cyclin D1 (Bromberg et al., 1998) and c-Myc (Bromberg et al., 1999) . Thus, Src activates Stat3, which in turn induces expression of genes that potentially contribute to oncogenesis by preventing apoptosis and stimulating cell cycle progression.
Src as a target for anti-cancer drugs
The prevalence of activated Src in cancer indicates that this protein may play a signi®cant role in the progression of many cancers, and thus, is a likely target for drug discovery eorts. Src activation has been shown to increase growth rates and invasion characteristics of tumors, and to decrease apoptosis in tumor cells. Reduced expression of any of these properties would potentially induce retarded tumor growth and reduction of metastatic tendencies. The recent use of Src inhibitors or antisense therapy in nude mouse studies , pancreatic cell growth , and leukemia cells (Roginskaya et al., 1999) supports the validity of this hypothesis. Numerous in vitro studies have been conducted to investigate the eects of Src speci®c inhibitors, general tyrosine kinase inhibitors, and growth factor receptor inhibitors. The challenge has been to develop inhibitors, which are not only speci®c for Src, but also stable in vivo and are bioavailable.
Conclusions
The role of c-Src in human cancer has evolved from a curious avian viral homolog with high transformation capacity to a candidate oncogene with a critical position in the signal transduction cascades that control cell growth. Clearly, Src does not act alone but works in concert with a large number of substrates, which orchestrate the processes of human cancer development and tumor progression. Moreover, there is a signi®cant amount of data supporting the in¯uence of Src on the development of the metastatic phenotype. Collectively, these observations linking Src to multiple processes that determine the clinical outcome of a tumor make it a promising target for drug discovery and targeting. Figure 1 The role of Src activation in promoting metastasis. Src activation can be viewed as central to the multiple signal transduction pathways necessary or sucient to induce the metastatic phenotype. Src does not act alone, but rather cooperates with other proteins and substrates whose interactions lead to transcription of metastasis promoting genes. Src activation can occur through a variety of mechanisms including interactions with receptor tyrosine kinases and integrin receptors. Some of these interactions require partnerships such as those between EGFR and Her2/neu or between intergrins, Fak, and Cas. Src activation in turn can lead to the activation of signal transduction pathways and to the activation of individual substrates, which may also impact on signal transduction pathways. The end result is the production of factors that enable the metastatic process such as those involved with growth, survival, invasion, migration, adhesion, and angiogenesis
